-+ 0.00%
-+ 0.00%
-+ 0.00%

Pfizer's 25-Valent Pneumococcal Vaccine Shows Strong Immune Responses in Phase 2 Infant Trial

PUBT·10/24/2026 15:18:49
Listen to the news
Pfizer's 25-Valent Pneumococcal Vaccine Shows Strong Immune Responses in Phase 2 Infant Trial
  • Pfizer presented Phase 2 results for its 25-valent pediatric pneumococcal vaccine candidate at IDWeek 2026, showing strong immune responses in infants.
  • Safety and tolerability were comparable to Prevnar 20, with no vaccine-related serious adverse events identified.
  • The candidate generated stronger responses against serotype 3 than Prevnar 20, while extending coverage to five additional serotypes.
  • Results support ongoing Phase 3 development, potentially expanding protection against invasive pneumococcal disease in U.S. children under five.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pfizer Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202610241118BIZWIRE_USPR_____20261024_BW078788) on October 24, 2026, and is solely responsible for the information contained therein.